Alivus Life Sciences share news, announcements and annual reports
NSE: ALIVUSBSE: 543322Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,397.40.
30 Oct: open ₹1,451.00, high ₹1,499.00, low ₹1,380.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,376 Cr502nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.94
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.79
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.35%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 23.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 11,47,21334.5% delivered
Alivus Life Sciences share news and announcements
284 announcements, routine notices left out, newest first. Page 5 of 6.
Nov 2023
13 Nov · Business
Oct 2023
20 Oct · Results
16 Oct · Analysts
13 Oct · Board meeting
4 Oct · Corporate action
4 Oct · Board meeting
4 Oct · Rating
Sep 2023
28 Sep · Public Announcement-Open Offer
23 Sep · Rating
21 Sep · Board meeting
1 Sep · Updates
Aug 2023
25 Aug · Updates
Jul 2023
21 Jul · Results
14 Jul · Analysts
13 Jul · Board meeting
May 2023
12 May · Business
Apr 2023
27 Apr · Related Party Transactions
27 Apr · Updates
27 Apr · Results
20 Apr · Analysts
19 Apr · Board meeting
Mar 2023
14 Mar · Corporate action
Feb 2023
Jan 2023
27 Jan · Results
18 Jan · Analysts
Dec 2022
Nov 2022
4 Nov · Related Party Transaction
Oct 2022
21 Oct · Management
21 Oct · Management